Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Moricizine HCl, a new orally active antiarrhythmic agent, induces its own hepatic metabolism and consequently may interfere with the metabolism of warfarin, a drug used commonly by cardiac patients that also is subject to extensive hepatic metabolism. Both drugs are also highly protein bound in plasma. To assess the possibility of an interaction, single-dose sodium warfarin (25 mg oral Coumadin, Du Pont Pharmaceuticals, Wilmington, DE) pharmacokinetics, pharmacodynamics; and plasma protein binding were examined in 12 healthy male volunteers 14 days before and 14 days after starting chronic oral moricizine HCl administration (250 mg every 8 hours). The terminal elimination rate constant of warfarin was increased by about 10% when measured in the presence of chronic moricizine administration. However, oral plasma clearance, apparent volume of distribution, maximum peak plasma concentration, time to reach peak concentration, and protein binding were unaffected. More importantly, there was no evidence of a pharmacodynamic interaction based on the prothrombin time profile. It was concluded that no clinically significant interaction occurs under these conditions.
Benedek
I H
IH
Du Pont Merck Pharmaceutical Company, Newark, Delaware 19714.
King
S Y
SY
Powell
R J
RJ
Agra
A M
AM
Schary
W L
WL
Pieniaszek
H J
HJ
D000328:Adult; D001798:Blood Proteins / Q000378:metabolism*; D004347:Drug Interactions; D006801:Humans; D008297:Male; D016293:Moricizine / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D011485:Protein Binding; D011517:Prothrombin Time; D014859:Warfarin / Q000493:pharmacokinetics* / Q000494:pharmacology
D001798:Blood Proteins; D016293:Moricizine; D014859:Warfarin